Home
Live Updates
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer : comparemela.com
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 -- AIM ImmunoTech Inc. today announced the publication of results from the Phase 1 study at Roswell Park...
Related Keywords
New York ,
United States ,
American ,
Pawel Kalinski ,
Shipra Gandhi ,
Roswell Park ,
Roswell Park Comprehensive Cancer Center ,
Immunotech Inc ,
Department Of Medicine At Roswell Park ,
Facebook ,
Team Science At Roswell Park ,
Roswell Park Care Network ,
Linkedin ,
National Cancer ,
Twitter ,
Senior Vice President ,
Steam Science ,
Roswell Park Shows Promise ,
Metastatic Triple Negative Breast Cancer ,
New York State ,
National Cancer Institute Designated ,
Upstate New ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.